-+ 0.00%
-+ 0.00%
-+ 0.00%

D. Boral Capital Maintains Buy on Immunic, Lowers Price Target to $4

Benzinga·02/13/2026 13:09:14
Listen to the news
D. Boral Capital analyst Jason Kolbert maintains Immunic (NASDAQ:IMUX) with a Buy and lowers the price target from $8 to $4.